Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TP53 mutation + Chr del(17p)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib + obinutuzumab Sensitive: C3 – Early Trials venetoclax + ibrutinib + obinutuzumab Sensitive : C3	venetoclax + ibrutinib + obinutuzumab Sensitive: C3 – Early Trials venetoclax + ibrutinib + obinutuzumab Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: C3 – Early Trials obinutuzumab + acalabrutinib Sensitive : C3	obinutuzumab + acalabrutinib Sensitive: C3 – Early Trials obinutuzumab + acalabrutinib Sensitive : C3